Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Asthma, Allergic Clinical Trial

Official title: A Phase 2 Multi-centre Randomized Double-blind Placebo-controlled Parallel Group Study to Examine the Effects of 24 Weeks Tezepelumab 210 mg sc q4wks on Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Status Not yet recruiting

Clinical Trial Summary

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.

Clinical Trial Description

The proposed study will address whether tezepelumab has the unique ability to improve AHR in participants with mild allergic asthma. This is a phase 2 multi-centre randomized double-blind placebo-controlled parallel-group study to examine the effects of 24 weeks tezepelumab 210 mg sc q4wks on methacholine airway hyperresponsiveness in participants with mild allergic asthma, stratified for sex and sensitivity to seasonal allergens. There are 9 study visits over a period of 27 weeks (Figure 1). Study procedures performed at Weeks -1, 8, 16 and 24 will be divided across 2 visits at least 48 hours apart for measurement of AHR to methacholine first, and mannitol at least 48 hours later. The screening period at Week -1 will determine eligibility. At Week -1, eligible allergic mild asthmatic participants will be randomized 1:1 to placebo or tezepelumab 210 mg subcutaneous administered monthly for a total of 24 weeks. AHR will be measured by methacholine and mannitol challenges at baseline (Week -1) performed at least 48 hours apart. Changes in AHR response will be measured by repeat methacholine and mannitol challenges at Weeks 8, 16 and 24. ;

Related Conditions & MeSH terms

• Asthma
• Asthma, Allergic
• Respiratory Hypersensitivity

• NCT number: NCT05740748
• Study type: Interventional
• Source: McMaster University
• Contact: Gail M Gauvreau, PhD
• Phone: 9055259140
• Email: gauvreau@mcmaster.ca
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 1, 2023
• Completion date: December 30, 2024